We are a team bound by a common purpose – to transform lives through cutting-edge Cell & Gene Therapies (CGT).
CGT growth relies on a robust supply of viral vectors, primarily AAV and Lenti.
SGVector’s process optimisation with lower costs modalities in the design and supply of viral vectors shall contribute to the innovation of CGT and bring affordable CGT to patients, globally.
At SGVector, we understand the critical role viral vectors play in propelling therapeutic advancements in Cell & Gene Therapies (CGT).
We are dedicated to accelerating our clients journey towards innovative therapies.
Co-founded by Dr Teo Cheng Peng, Mr Sukh Chopra, Professor Steven Myint and Dr Gayatri Sharma, and supported by established research and medical institutions.
Also supported by investors with strong strategic alignment. A nimble team of dedicated scientists that have joined SGVector in belief of our value proposition to contribute significantly in CGT.
Eric Soon – MSc, leads our Manufacturing Science & Technology (MSAT) team with more than a decade of experience in research and clinical production of viral vectors and monoclonal antibodies. He works collaboratively with our global industry expert advisors led by Dr Shekar Ganesa – PhD (Senior Technical Advisor) and Dr Ping Law – PhD (Senior Assay Development Advisor) as well as with our research partners in A*STAR in vector design, process optimization and new modalities.
Eric’s unwavering commitment to fostering a collaborative and inclusive environment within the team is well-recognized.
Shekar brings 30+ years of experience in Process Development (cell line development/banking, upstream, downstream, formulation and analytical development activities) with a proven record of accomplishment of global regulatory submissions/approvals at Genzyme-Sanofi, Amgen and MassBiologics for monoclonal antibodies and gene therapy (AAV and Lentivirus) in adherent and suspension adapted HEK 293 cells.
At MassBiologics, Shekar’s team lead the process development, scale-up/technology transfer and regulatory (FDA and EMEA) approval of UPSTAZA™ (eladocagene exuparvovec, AAV2-AADC) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.
Ping specialises in QC assays and large-scale enrichment of different cell types, including cell processing for clinical therapies such as stem cell transplantation and CAR-T. He was a Director at Miltenyi Biotec (CDMO business), San Jose, CA overseeing GMP manufacturing (cell therapy products), MSAT and process development. He also held key cell processing roles held at NUH Dept of orthopaedic surgery (Singapore), St Jude (USA) and UCSD (USA).
Our dedicated research scientists come from academia, research and development government agencies, pharmaceutical organisations and global CDMOs. They are the driving force behind our experiments. They bring extensive knowledge in cell and molecular biology, vector design, upstream, downstream process development, analytical method development/qualification and subsequent process scale-up and method transfer activities.
Looking ahead, our technical team is committed to pushing the boundaries of viral vector innovation. Our aim is to expand our viral vector development initiatives for various disease areas by exploring cutting-edge delivery technologies and strengthen our collaborations with our partner research institutions as well as clinical partners.
Haematologist. Founding member of TalkMED Group Ltd (SGX listed) and Parkway Cancer Centre at Gleneagles Hospital. Chairman of Gleneagles Hospital Blood Transfusion Committee. Co-founder of StemCord and StemMed Pte Ltd. CEO of CellVec (a Lenti Viral Vector GMP CDMO in Singapore).
Developed the Autologous Stem Cell Transplant program for solid tumours at Singapore General Hospital. Spearheaded the Bone Marrow and Peripheral Blood Stem Cell Transplant research at the National University Hospital.
Key member of various prestigious medical bodies including Singapore Society of Haematology, Singapore Bone Marrow Donor Programme, Singapore Society of Oncology, Society of Transplantation (Singapore), International Society of Haematology and Graft Engineering and the International Society of Haematology.
Director LoveNils, a Charity Organisation, catering to the needs of children with cancer. Chairman of the Board & Remuneration Committee Shanaya Limited (SGX listed). Lecturer with Singapore’s leading Universities on management.
Regional MD Civica, a Smart Software & Solutions provider globally. World Bank funded project consultant in Capacity Building, Afghanistan. Director Administration, Lee Kuan Yew School of Public Policy, NUS. Colonel (Retired) Singapore Armed Forces.
Award recipient from Singapore’s President for distinguished and meritorious service (PBS). Award recipient from various Singapore Government agencies recognising his contributions to promote social cohesion in Singapore.
Immunologist. Executive Director Health Innovation Manchester (UK).
Founding Non-Executive Director of NHSA (UK). Senior fellow to A*STAR. Adjunct Professor at Duke-NUS (Singapore). Chairman of Inex Pte Ltd (Singapore). Professor & Dean of Medicine & Health at University of Surrey (UK) and Professor/Chairman of Microbiology & Immunology at the University of Leicester (UK). Global Medical Director at GSK. Chairman Green Signal Bio (India). Fellow of the Institute of Knowledge Transfer, the Royal College of Physicians and the Royal Society of Medicine (UK).
Authored over 120 peer reviewed publications and 6 books. Instrumental in over 50 successful IND and 12 NDA submissions.
COO of CellVec (a Lenti Viral Vector GMP CDMO in Singapore) with expertise in commercial strategy, operations, marketing, and market access – shaping and achieving the company’s regional and global growth ambitions.
Commercialised rare oncolytic and genetic disorder products at Cell and Gene Therapy Catapult (CGTC, UK) and Oxford University Hospitals (UK). Served as the Entrepreneur in Residence at Duke-NUS (Singapore) and led the Institute’s first gene therapy asset acquisition to big pharma overseeing the strategic planning for their gene therapy assets. First non-European recipient of the CHRAT Fellow at Institute of Child Health, University College London – Great Ormand Street Hospital (UK).